Adeno-associated virus (AAV) has been researched as a viral vector in gene therapy for cancer treatment as an oncolytic virus. Currently there are not any FDA approved AAV cancer treatments, as the first FDA approved AAV treatment was approved December 2017.[1] However, there are many Oncolytic AAV applications that are in development and have been researched.
This article's factual accuracy is disputed. Relevant discussion may be found on the talk page. Please help to ensure that disputed statements are reliably sourced.(August 2022) (Learn how and when to remove this message)
^"First AAV-Delivered Gene Therapy for Inherited Disease Approved by FDA". Articles. ClinicalOMICs. 20 December 2017. Retrieved 2018-04-17.
(AAV) has been researched as a viral vector in gene therapy for cancer treatment as an oncolytic virus. Currently there are not any FDA approved AAV cancer...
symporter (MV-NIS) OncolyticAAV Oncovirus, virus that can cause cancer Ferguson MS, Lemoine NR, Wang Y (2012). "Systemic delivery of oncolytic viruses: hopes...
vector for gene therapy and also as an oncolytic virus. Of the many different viruses being explored for oncolytic potential, an adenovirus was the first...
treat diseases. There are three main branches of virotherapy: anti-cancer oncolytic viruses, viral vectors for gene therapy and viral immunotherapy. These...
utilize adeno-associated viruses (AAVs) and lentiviruses for performing gene insertions, in vivo and ex vivo, respectively. AAVs are characterized by stabilizing...
Global Information